Evolution of Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials: A Clinical Trial Databank Analysis

An Outtier(KU Leuven), Marc Ferrante(KU Leuven), Bram Verstockt(Universitair Ziekenhuis Leuven), Liese Barbier(KU Leuven), João Sabino(KU Leuven), Isabelle Huys(KU Leuven), Rosanne Janssens(KU Leuven), Séverine Vermeire(KU Leuven)
United European Gastroenterology Journal
December 19, 2024
10.1002/ueg2.12731
Cited by 6

Related Papers

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
|Gut|2013|1.9k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
|Journal of Crohn s and Colitis|2019|1.4k